This explainer provides an overview of the federal “Ending the HIV Epidemic” initiative and explores issues that might mitigate or facilitate its success.
- view as grid
- view as list
This tracker provides up-to-date data on federal Ending the HIV Epidemic (EHE( funding, including an overview of funding mechanisms by year, agency, grant mechanism, and jurisdiction. It will be updated over time.
This data note provides a top line overview of the federal FY2021 HIV Budget Request and includes comparisons to FY2020 funding.
This updated fact sheet highlights the impact of HIV/AIDS on women in the United States, providing current data and trends over time.
The poll examines the public’s knowledge and attitudes about STIs and finds few are aware of how common STIs are among adults in the U.S.
Public Knowledge and Attitudes About Sexually Transmitted Infections: KFF Polling and Policy Insights
A new KFF poll provides new data on the public’s knowledge and attitudes about sexually transmitted infections and finds majorities of the public unaware of how common STIs are among adults in the U.S.
More people have health insurance than ever before under the Affordable Care Act (ACA), which emphasizes preventive care, including no-cost HIV and STI counseling and screening for recommended populations. This fact sheet examines trends and disparities in STI prevalence, reviews the STI screening and preventive care coverage policies for private insurance and public programs, and discusses coverage gaps and confidentiality concerns in the provision of these services.
This updated fact sheet highlights the epidemic’s impact on Black Americans, providing current data and trends over time. Black Americans have been disproportionately affected by HIV/AIDS since the epidemic’s beginning, and that disparity has deepened over time. Black Americans account for more new HIV diagnoses, people estimated to be living with HIV, and HIV-related deaths than any other racial/ethnic group in the U.S.
This data note examines the potential implications of work requirements for people with HIV, a population that relies heavily on Medicaid and for whom there are important clinical and public health reasons for maintaining consistent access to insurance coverage and HIV care.
Drug price concerns in the U.S., including for antiretrovirals, the mainstay of HIV treatment and, increasingly prevention, have prompted the introduction of several policy proposals. One proposal would require manufacturers to provide a rebate to the federal government if prices increase faster than inflation. We assessed list price changes for ARVs under Part D, which is required to cover all or substantially all ARVs.